Biocon has announced that Shreehas Tambe will assume the role of Managing Director and Chief Executive Officer for a five-year term, effective April 1, 2026, subject to shareholder approval. The board has also approved his appointment as an Additional Director from the same date, reinforcing leadership continuity at a pivotal time for the organization.

Currently serving as CEO and MD of Biocon Biologics, Tambe brings nearly three decades of experience within the Biocon group. He has played a critical role in scaling the company’s global biosimilars business, driving expansion across key international markets and strengthening its position in the biopharmaceutical sector.

With deep expertise spanning research and development, manufacturing, and commercial strategy, Tambe is well positioned to lead Biocon into its next phase of growth. His leadership is expected to further accelerate innovation, enhance global competitiveness, and strengthen the company’s focus on affordable, high-quality biologics.